Clinical Trials Browser

Phase 2 × INDUSTRY × belantamab mafodotin × Clear all

NCT07227311 2026-06-02

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Phase 2 Recruiting

Multiple Myeloma

NCT07614360 2026-05-29

DREAMM-16

Phase 2 Not yet recruiting

Multiple Myeloma

NCT05064358 2026-05-05

DREAMM 14

Phase 2 Completed

177 enrolled 37 charts

Multiple Myeloma, Recurrence

NCT07224672 2026-03-17

ALANIS

Phase 2 Not yet recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis